Reduced Expression Level of Protein Phosphatase PPM1E Serves to Maintain Insulin Secretion in Type 2 Diabetes
Diabetes · 2023
DOI: 10.2337/db22-0472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Sevda Gheibi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular Metabolism, Lund University Diabetes Centre, Malmö, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin-Secreting Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Royal Physiographic Society of Lund, Forskningsrdet om Hlsa, Arbetsliv och Vlfrd, Stiftelsen Lars Hiertas Minne.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Reversible phosphorylation is an important regulatory mechanism. Regulation of protein phosphorylation in β-cells has been extensively investigated, but less is known about protein dephosphorylation. To understand the role of protein dephosphorylation in β-cells and type 2 diabetes (T2D), we first examined mRNA expression of the type 2C family (PP2C) of protein phosphatases in islets from T2D donors. Phosphatase expression overall was changed in T2D, and that of PPM1E was the most markedly downregulated. PPM1E expression correlated inversely with HbA1c. Silencing of PPM1E increased glucose-stimulated insulin secretion (GSIS) in INS-1 832/13 cells and/or islets from patients with T2D, whereas PPM1E overexpression decreased GSIS. Increased GSIS after PPM1E silencing was associated with decreased oxidative stress, elevated cytosolic Ca2+ levels and ATP to ADP ratio, increased hyperpolarization of the inner mitochondrial membrane, and phosphorylation of CaMKII, AMPK, and acetyl-CoA carboxylase. Silencing of PPM1E, however, did not change insulin content. Increased GSIS, cell viability, and activation of AMPK upon metformin treatment in β-cells were observed upon PPM1E silencing. Thus, protein dephosphorylation via PPM1E abrogates GSIS. Consequently, reduced PPM1E expression in T2D may be a compensatory response of β-cells to uphold insulin secretion under metabolic duress. Targeting PPM1E in β-cells may thus represent a novel therapeutic strategy for treatment of T2D. ARTICLE HIGHLIGHTS
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Molecular Metabolism, Lund University Diabetes Centre, Malmö, Sweden.
- The Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Unit of Islet Cell Exocytosis, Lund University Diabetes Centre, Malmö, Sweden.
- Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden.
ORCID-Profile: Sevda Gheibi, Sebastian Kalamajski, Malin Fex, Hindrik Mulder
Förderung
- Royal Physiographic Society of Lund
- Forskningsrdet om Hlsa, Arbetsliv och Vlfrd
- Stiftelsen Lars Hiertas Minne
- Albert Phlssons Foundations
- Hjelt
- Novo Nordisk
Zitieren
APA
Gheibi, S., Cataldo, L. R., Hamilton, A., Huang, M., Kalamajski, S., Fex, M., & Mulder, H. (2023). Reduced Expression Level of Protein Phosphatase PPM1E Serves to Maintain Insulin Secretion in Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db22-0472
Vancouver
Gheibi S, Cataldo LR, Hamilton A, Huang M, Kalamajski S, Fex M, et al. Reduced Expression Level of Protein Phosphatase PPM1E Serves to Maintain Insulin Secretion in Type 2 Diabetes. Diabetes. 2023. doi:10.2337/db22-0472
BibTeX
@article{Gheibi2023,
author = {Gheibi, Sevda and Cataldo, Luis Rodrigo and Hamilton, Alexander and Huang, Mi and Kalamajski, Sebastian and Fex, Malin and Mulder, Hindrik},
title = {Reduced Expression Level of Protein Phosphatase PPM1E Serves to Maintain Insulin Secretion in Type 2 Diabetes},
journal = {Diabetes},
year = {2023},
doi = {10.2337/db22-0472}
}
EUVIMED